CANTEX Trademark

Trademark Overview

On Wednesday, June 14, 2023, a trademark application was filed for CANTEX with the United States Patent and Trademark Office. The USPTO has given the CANTEX trademark a serial number of 98043024. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Thursday, September 12, 2024. This trademark is owned by Cantex Pharmaceuticals, Inc.. The CANTEX trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, Medical & Beauty Services & Agricultural Services, Personal, and Legal & Social Services categories with the following description:

Pharmaceuticals, namely, Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses; Pharmaceutical preparations for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for inhibiting Receptor for Advanced Glycation End products (RAGE) interactions, for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Pharmaceutical preparations for use in personalized medicine and targeted therapy in the field of Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases,...

Licensing of pharmaceuticals and drug discovery technologies

Providing medical and scientific research information about the diagnosis and treatment of diseases, namely, infectious diseases, viral diseases, and autoimmune diseases; Providing information in the fields of health, wellness, and pharmaceuticals via a website; all of the foregoing related to Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses

Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Development of new drugs for the prevention and treatment of cancer and other serious illnesses; Design and testing of new drugs and therapies; Medical and scientific research in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Medical and scientific research consulting in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Biological testing and research in the field of pharmaceuticals; all of the foregoing related to Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases
cantex

General Information

Serial Number98043024
Word MarkCANTEX
Filing DateWednesday, June 14, 2023
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateThursday, September 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceuticals, namely, Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses; Pharmaceutical preparations for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for inhibiting Receptor for Advanced Glycation End products (RAGE) interactions, for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Pharmaceutical preparations for use in personalized medicine and targeted therapy in the field of Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases
Goods and ServicesLicensing of pharmaceuticals and drug discovery technologies
Goods and ServicesProviding medical and scientific research information about the diagnosis and treatment of diseases, namely, infectious diseases, viral diseases, and autoimmune diseases; Providing information in the fields of health, wellness, and pharmaceuticals via a website; all of the foregoing related to Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses
Goods and ServicesProviding medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Development of new drugs for the prevention and treatment of cancer and other serious illnesses; Design and testing of new drugs and therapies; Medical and scientific research in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Medical and scientific research consulting in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Biological testing and research in the field of pharmaceuticals; all of the foregoing related to Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 18, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, July 18, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, July 18, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, July 18, 2023
Primary Code045
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCantex Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWeston, FL 33326

Trademark Events

Event DateEvent Description
Wednesday, May 29, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, May 29, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Saturday, June 17, 2023NEW APPLICATION ENTERED
Tuesday, July 18, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 4, 2024ASSIGNED TO EXAMINER
Tuesday, March 12, 2024NON-FINAL ACTION WRITTEN
Tuesday, March 12, 2024NON-FINAL ACTION E-MAILED
Tuesday, March 12, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, September 12, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, September 12, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, September 12, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED

Related Keywords

cantex diseases treatment infectious cancer other autoimmune illnesses serious namely field